V2 sact_regimen
781,388 rows · 12 columns
| ENCORE_PATIENT_ID | MERGED_REGIMEN_ID | HEIGHT_AT_START_OF_REGIMEN | WEIGHT_AT_START_OF_REGIMEN | INTENT_OF_TREATMENT | DATE_DECISION_TO_TREAT | START_DATE_OF_REGIMEN | MAPPED_REGIMEN | CLINICAL_TRIAL | CHEMO_RADIATION | BENCHMARK_GROUP | LINK_NUMBER |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 20214327 | 20080637 | 1.71 | 75.4 | Palliative (P) | 2019-07-21 | 2019-07-21 | Cape+Cisplatin+Trastuzumab Load | 02 | N | CAPECITABINE + CISPLATIN + TRASTUZUMAB | 101542315 |
| 20214328 | 20080638 | 1.8 | 0 | 03 | null | 2017-10-19 | LANREOTIDE | 02 | N | LANREOTIDE | 100593973 |
| 20214329 | 20080639 | 0 | 99.3 | Adjuvant (A) | 2018-08-05 | 2018-08-12 | Imatinib 400mg | 02 | N | IMATINIB | 100187705 |
| 20214332 | 20080641 | 0 | 63.2 | Palliative (P) | null | 2016-10-13 | Cape+Cisplatin+Trastuzumab Main | 02 | N | TRIAL | 100579633 |
| 20214333 | 20080642 | 0 | 47.25 | Palliative (P) | 2019-05-24 | 2019-06-23 | CAPECITABINE + CISPLATIN + Trastuzumab | 02 | N | LANREOTIDE | 101603358 |
| 20214334 | 20080643 | 1.84 | 84.6 | 03 | 2019-06-21 | 2019-06-21 | LANREOTIDE | N | N | LANREOTIDE | 100016447 |
| 20214335 | 20080644 | 1.6 | 73.2 | Neo-adjuvant (N) | 2016-09-07 | 2016-09-07 | Trial Unspecified | 01 | N | TRIAL | 101241464 |
| 20214337 | 20080645 | 1.61 | 58.05 | Palliative (P) | 2019-07-15 | 2019-07-24 | HCX (Cape + Cisp + Tras) - Main | 02 | N | CAPECITABINE + CISPLATIN + TRASTUZUMAB | 100617183 |
| 20214339 | 20080647 | 1.52 | 49.4 | Curative (C) | 2016-04-05 | 2016-04-15 | FLUOROURACIL + MITOMYCIN + RT | N | Y | FLUOROURACIL + MITOMYCIN + RT | 101380360 |
| 20214340 | 20080648 | 1.8 | 73.3 | Palliative (P) | 2016-05-28 | 2016-06-26 | Trial Unspecified | 01 | N | TRIAL | 100067195 |
| 20214342 | 20080649 | 1.63 | 0 | Adjuvant (A) | 2019-01-16 | 2019-01-30 | CAPECITABINE + CISPLATIN + Trastuzumab | 02 | N | IMATINIB | 101693286 |
| 20214343 | 20080650 | 1.78 | 0 | Curative (C) | 2019-11-13 | 2019-12-03 | Fluorouracil+Mitomycin+RT (Anal Ca) | null | Y | FLUOROURACIL + MITOMYCIN + RT | 101292578 |
| 20214345 | 20080651 | 0 | 50 | Palliative (P) | null | 2019-03-25 | IMATINIB | 02 | N | IMATINIB | 101136384 |
| 20214346 | 20080652 | 1.8 | null | Curative (C) | 2017-07-28 | 2017-08-08 | Fluorouracil+Mitomycin+RT (Anal Ca) | 02 | Y | FLUOROURACIL + MITOMYCIN + RT | 100824696 |
| 20214347 | 20080653 | null | 76.1 | Palliative (P) | 2016-03-08 | 2016-03-10 | Trial Unspecified | 1 | N | TRIAL | 100657530 |
| 20214348 | 20080654 | 1.8 | 82.9 | Palliative (P) | 2018-10-01 | 2018-10-18 | LANREOTIDE | 02 | N | LANREOTIDE | 100751918 |
| 20214349 | 20080655 | 1.69 | 70.2 | Palliative (P) | 2019-07-09 | 2019-07-18 | Cape+Cisplatin+Trastuzumab Load | 02 | N | CAPECITABINE + CISPLATIN + TRASTUZUMAB | 101202817 |
| 20214350 | 20080656 | 1.76 | 80.4 | Curative (C) | 2018-04-30 | 2018-05-12 | Fluorouracil+Mitomycin+RT (Anal Ca) | N | N | FLUOROURACIL + MITOMYCIN + RT | 101540692 |
| 20214351 | 20080657 | 1.62 | 76.1 | Neo-adjuvant (N) | null | 2018-05-16 | Trial Unspecified | 01 | Y | TRIAL | 101169117 |
| 20214352 | 20080658 | 1.78 | 79.8 | Palliative (P) | 2017-07-20 | 2017-07-20 | Trial Unspecified | 01 | N | TRIAL | 100682069 |
| 20214353 | 20080659 | 1.54 | null | Palliative (P) | 2017-09-04 | 2017-09-11 | Cape+Cisplatin+Trastuzumab Load | 02 | N | CETUXIMAB + FLUOROURACIL + IRINOTECAN | 101311220 |
| 20214354 | 20080660 | 1.56 | 83.4 | Palliative (P) | 2016-11-18 | 2016-11-19 | SIEGE TRIAL | N | N | TRIAL | 100169221 |
| 20214356 | 20080661 | 1.68 | 75.3 | Palliative (P) | 2019-12-30 | 2019-12-30 | Trial Unspecified | 01 | N | TRIAL | 100299086 |
| 20214357 | 20080662 | null | null | Palliative (P) | null | 2018-03-10 | LANREOTIDE | 02 | N | LANREOTIDE | 100501724 |
| 20214360 | 20080664 | 1.69 | 81.5 | Palliative (P) | 2018-03-08 | 2018-03-23 | Cape+Cisplatin+Trastuzumab Load | 02 | N | CAPECITABINE + CISPLATIN + TRASTUZUMAB | 101790358 |
| 20214361 | 20080665 | 1.73 | 78.5 | Curative (C) | 2017-04-19 | 2017-05-14 | FLUOROURACIL + MITOMYCIN + RT | N | Y | FLUOROURACIL + MITOMYCIN + RT | 101585538 |
| 20214362 | 20080666 | 1.74 | 116 | Palliative (P) | null | 2018-02-25 | CAPECITABINE + CISPLATIN + Trastuzumab | 02 | N | CETUXIMAB + FLUOROURACIL + IRINOTECAN | 101745274 |
| 20214363 | 20080667 | 1.58 | 78.75 | Palliative (P) | 2018-04-29 | 2018-05-03 | Trial Unspecified | Y | N | TRIAL | 101134149 |
| 20214364 | 20080668 | 1.76 | 65.3 | Curative (C) | 2017-11-12 | 2017-12-23 | Fluorouracil+Mitomycin+RT (Anal Ca) | N | Y | FLUOROURACIL + MITOMYCIN + RT | 101613455 |
| 20214365 | 20080669 | 0 | 101 | 03 | 2017-09-03 | 2017-09-04 | LANREOTIDE | 2 | N | LANREOTIDE | 101048653 |
| 20214366 | 20080670 | 1.75 | 93.8 | Curative (C) | 2017-08-28 | 2017-09-14 | HCX (Cape + Cisp + Tras) - Load | 02 | null | CAPECITABINE + CISPLATIN + TRASTUZUMAB | 101259361 |
| 20214367 | 20080671 | null | 73.5 | Adjuvant (A) | 2016-07-25 | 2016-08-15 | CAPECITABINE + CISPLATIN + Trastuzumab | 02 | N | IMATINIB | 100259294 |
| 20214369 | 20080672 | 1.88 | 94.3 | Palliative (P) | null | 2021-10-04 | Cetuximab + FLUOROURACIL + FOLINIC ACID + IRINOTECAN | 02 | N | CETUXIMAB + FLUOROURACIL + IRINOTECAN | 100426873 |
| 20214370 | 20080673 | 1.6 | 72 | Palliative (P) | 2019-12-18 | 2019-12-23 | HCX | 02 | N | CAPECITABINE + CISPLATIN + TRASTUZUMAB | 100854982 |
| 20214371 | 20080674 | 1.6 | 78.4 | Palliative (P) | 2019-09-29 | 2019-09-29 | Imatinib 400mg | 02 | N | IMATINIB | 100651580 |
| 20214372 | 20080675 | 1.73 | 63.3 | Palliative (P) | 2016-10-29 | 2016-11-18 | Cape+Cisplatin+Trastuzumab Load | 02 | N | CAPECITABINE + CISPLATIN + TRASTUZUMAB | 100718976 |
| 20214373 | 20080676 | 1.74 | 57.8 | Palliative (P) | 2019-10-09 | 2019-10-30 | CAPECITABINE + CISPLATIN + Trastuzumab | null | N | CETUXIMAB + FLUOROURACIL + IRINOTECAN | 100971146 |
| 20214374 | 20080677 | 1.84 | 62 | Palliative (P) | 2016-10-13 | 2016-10-27 | CAPECITABINE + CISPLATIN + Trastuzumab | 02 | N | CETUXIMAB + FLUOROURACIL + IRINOTECAN | 100371394 |
| 20214375 | 20080678 | 1.75 | 60 | null | 2019-11-09 | 2019-11-21 | CAPECITABINE + CISPLATIN + Trastuzumab | 02 | null | LANREOTIDE | 100869684 |
| 20214376 | 20080679 | 1.7 | 74.1 | null | 2018-07-01 | 2018-07-01 | HCX (Cape + Cisp + Tras) - Load | 02 | null | FLUOROURACIL + MITOMYCIN + RT | 100706747 |
| 20214377 | 20080680 | 1.74 | 47.8 | Palliative (P) | 2018-08-05 | 2018-08-05 | Cape+Cisplatin+Trastuzumab Load | 02 | N | CAPECITABINE + CISPLATIN + TRASTUZUMAB | 101453521 |
| 20214378 | 20080681 | 1.69 | 86.2 | null | 2016-06-04 | 2016-06-05 | Cape+Cisplatin+Trastuzumab Load | 02 | null | IMATINIB | 100764959 |
| 20214380 | 20080683 | 1.67 | 87.9 | Curative (C) | 2019-04-03 | 2019-05-14 | Fluorouracil+Mitomycin+RT (Anal Ca) | N | Y | FLUOROURACIL + MITOMYCIN + RT | 101707416 |
| 20214381 | 20080684 | 1.71 | 90.5 | Palliative (P) | 2016-04-21 | 2016-04-21 | Cetuximab + FOLFIRI cycle 2 onwards | 02 | N | CETUXIMAB + FLUOROURACIL + IRINOTECAN | 101330039 |
| 20214382 | 20080685 | 1.54 | 116.4 | Adjuvant (A) | 2019-11-08 | 2019-11-19 | CAPECITABINE + CISPLATIN + Trastuzumab | 02 | N | IMATINIB | 100301551 |
| 20214383 | 20080686 | 1.68 | 78.6 | Curative (C) | 2017-05-01 | 2017-05-10 | Fluorouracil+Mitomycin+RT (Anal Ca) | N | Y | FLUOROURACIL + MITOMYCIN + RT | 100238147 |
| 20214384 | 20080687 | 1.81 | 73.1 | Curative (C) | null | 2018-04-11 | Fluorouracil+Mitomycin+RT (Anal Ca) | 2 | N | FLUOROURACIL + MITOMYCIN + RT | 101004453 |
| 20214385 | 20080688 | 1.66 | 92 | Palliative (P) | 2019-04-26 | 2019-04-26 | Trial Unspecified | 01 | N | TRIAL | 100402622 |
| 20214386 | 20080689 | 1.7 | 65.4 | Palliative (P) | 2019-11-30 | 2019-11-30 | LANREOTIDE | 02 | N | LANREOTIDE | 101589378 |
| 20214387 | 20080690 | 1.62 | 79.3 | Palliative (P) | 2020-10-27 | 2020-11-03 | CETUXIMAB + IRINOTECAN + MDG | 02 | N | CETUXIMAB + FLUOROURACIL + IRINOTECAN | 100206461 |